| Literature DB >> 14513375 |
H Sindermann1, S L Croft, K R Engel, W Bommer, H J Eibl, C Unger, J Engel.
Abstract
Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14513375 DOI： 10.1007/s00430-003-0201-2
Source DB: PubMed Journal: Med Microbiol Immunol ISSN： 0300-8584 Impact factor: 3.402